Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.50
  • Today's Change0.00 / 0.00%
  • Shares traded11.71k
  • 1 Year change-21.63%
  • Beta0.5680
Data delayed at least 15 minutes, as of Jun 06 2024 19:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

  • Revenue in USD (TTM)117.10k
  • Net income in USD-161.61m
  • Incorporated1984
  • Employees--
  • Location
    Opthea LtdSuite 0403Level 4, 650 Chapel Street, South YarraMELBOURNE 3141AustraliaAUS
  • Phone+61 39826-0399
  • Fax+61 39824-0083
  • Websitehttps://opthea.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hirequest Inc36.44m5.81m182.42m139.0031.052.8521.205.010.41970.37032.634.570.3367--0.7606262,187.105.3710.328.6414.51----15.9429.00--17.180.206131.7622.39-17.21-46.2645.8725.21--
Lucas GC Ltd203.54m10.73m183.00m361.0017.066.8316.060.8990.13480.13482.560.3375.53--22.52563,831.6029.33--50.43--28.40--5.30----75.830.1669--92.28--133.69------
Bridger Aerospace Group Holdings Inc71.85m-76.86m198.40m148.00------2.76-1.76-1.761.320.27570.279595.0728.56485,470.50-20.52---22.21--39.74---73.43--1.23-1.630.9434--43.80--102.58------
Armlogi Holding Corp135.04m13.92m212.52m122.0015.278.4014.071.570.33150.33153.220.6027------1,106,922.00--------19.06--10.31----296.830.019--141.02--602.72------
Wewards Inc0.00-695.37k217.12m-----------0.0065-0.00650.00-0.1220.00-------80.33-39.25---84.93-------9,087.72---0.3752--------68.09------
Opthea Ltd (ADR)117.10k-161.61m224.18m--------1,914.46-2.48-2.480.0018-0.56620.0007--0.1772---100.84---116.05---99.74---138,008.10-----29.641.35--19.55---53.55------
Outbrain Inc921.01m10.81m224.19m942.0025.401.047.360.24340.18070.180717.384.421.34--5.45977,715.501.57--2.59--20.11--1.17------0.3523---5.67--141.67------
Blade Air Mobility Inc231.42m-50.12m232.81m231.00--0.9814--1.01-0.6734-0.67343.043.070.7648--11.571,001,831.00-16.56---17.94--21.68---21.66------0.00--54.11---105.71------
Performant Financial Corp115.35m-7.32m236.25m958.00--3.04--2.05-0.0959-0.09591.511.011.14--4.54120,405.00-7.21-10.44-8.17-13.50-----6.34-9.97---4.030.0605--4.18-6.08-15.02---11.53--
EVI Industries Inc357.46m4.79m265.67m705.0057.521.9922.930.74320.36420.364227.1610.531.434.356.99507,032.602.202.973.174.1229.5626.001.532.010.79663.920.14096.7332.4918.75132.1918.3634.93--
TrueCar Inc162.78m-36.05m270.42m324.00--1.73--1.66-0.4009-0.40091.801.700.7696--11.14502,401.30-17.04-15.56-19.52-17.4190.0091.22-22.15-24.45----0.00---1.74-13.8858.07---7.14--
Vasta Platform Ltd294.44m-11.31m283.51m2.01k--0.32456.530.9629-0.126-0.1263.5710.790.20652.002.08146,344.10-0.7866-1.04-0.9266-1.2264.0060.14-3.81-6.380.84120.65290.157--17.5614.21-53.50--19.24--
Data as of Jun 06 2024. Currency figures normalised to Opthea Ltd's reporting currency: US Dollar USD

Institutional shareholders

8.40%Per cent of shares held by top holders
HolderShares% Held
Regal Funds Management Pty Ltd.as of 31 Mar 20242.91m3.51%
Baker Bros. Advisors LPas of 31 Mar 20242.18m2.63%
Victory Capital Management, Inc. (Investment Management)as of 31 Mar 2024855.52k1.03%
Teacher Retirement System of Texasas of 31 Mar 2024625.00k0.75%
Pengana Capital Ltd.as of 31 Jan 2024270.42k0.33%
Millennium Management LLCas of 31 Mar 202473.58k0.09%
BMO Asset Management Corp.as of 31 Mar 202453.19k0.06%
Frazier Financial Advisors LLCas of 31 Mar 2024355.000.00%
Morgan Stanley & Co. LLCas of 31 Mar 202421.000.00%
Steward Partners Investment Advisory LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Jan 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.